About US
Contact us
-
With new cash on its way, it's back to buying for deal-happy Allergan, CEO saysOn Monday, Allergan ($AGN) agreed to sell off a $40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries ($TEVA). But CEOBrent Saunde2015/7/29
-
About that brand/generics hybrid thing? Make that brands only, Allergan says with Teva dealIt's been less than 8 months since the company formerly known asActavisagreed to swallow Allergan ($AGN), taking a $66 billion plunge into branded sales and pledging to run its branded and generics bu2015/7/28
-
Aegerion dumps CEO who got it into FDA trouble for talking too freelyAegerion Pharmaceuticals ($AEGR) CEO Marc Beer may be a fast talker but he has been a bit of a slow walker when it comes to giving up his position as CEO. The executive, who got the company into troub2015/7/28
-
Cancer docs try to rally public behind plan to fight drug pricesCancer doctors at the famed Mayo Clinic have been up in arms about escalating prices ofcancer drugs. Now they have recruited a bunch of colleagues and are trying to rile up the public in hopes of star2015/7/27
-
UnitedHealth uses newfound scale to negotiate pay-for-performance dealsNewly bulked-up UnitedHealth ($UNH) now boasts the U.S.' third largest pharmacy benefits business--and it's using its scale to push for refunds when meds don't live up to their billing, it says. The2015/7/27
-
The stichting strikes back: Mylan's Dutch foundation snaps up shares to block Teva buyWannabe acquirer Teva ($TEVA) has built up a 4.6% stake in generics rival Mylan ($MYL)--and that's enough for the newly Dutch pharma. Mylan's independent foundation--known in Dutch as a stichting--has2015/7/24
-
Novartis whacks 3 Sandoz plants, 770 jobs, despite generic units' sales growthA 10% revenue expansion in Novartis' ($NVS) generics unitSandozwas one of the positives in the Swiss drugmaker's second quarter earnings, but it will not keep the drugmaker from closing three Sandoz p2015/7/24
-
CFDA releases 2014 Annual Report for National Medical Device Adverse Event MonitoringChina Food and Drug Administration (CFDA) recently released the 2014 Annual Report for National Medical Device Adverse Event Monitoring, which includes the general situation of medical device adverse2015/7/23
-
Genzyme's Cerdelga success bodes well for Fabry prospectSanofi's ($SNY)Genzymeis testing an oral drug forFabry disease, which would go up against its own Fabrazyme if and when it wins approval. But the company knows a thing or two about bringing new pills2015/7/23
-
New obesity meds 'pretty safe,' but some side effects bear watching: AdverseEventsCardiac safety concerns forobesitydrugs aren't a new phenomenon: Fen-Phen and Meridia were notoriously yanked from shelves for troubling side effects. But companies selling a new generation of drugs--2015/7/23